8-K Announcements
6Material company update
Jan 7, 2026·SEC
Material company update
Dec 2, 2025·SEC
Material company update
Oct 16, 2025·SEC
Windtree Therapeutics, Inc.(WINT)Earnings, Financials & Key Ratios
WINT•NASDAQ
$0.01
Price updated Jul 7, 2026
AboutWindtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.Show more
- Revenue$0
- EBITDA-$25M-42.8%
- Net Income-$5M+73.0%
- EPS (Diluted)-104.35+97.8%
- ROE-81.98%+72.9%
WINT Price & Volume
Windtree Therapeutics, Inc. (WINT) stock price & volume — 10-year historical chart
Loading chart...
Critical Liquidity Shortfall Threatens Clinical Pipeline Viability
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Critical liquidity and delisting
Key Thesis Takeaways
- Windtree Therapeutics faces an existential threat as its clinical-stage business model continues to generate significant net losses, evidenced by a $28.1 million net loss in 2025Q3.
- The company's reliance on external capital to fund R&D expenditures of $1.9 million per quarter, coupled with a near-total depletion of cash reserves to $204,000, suggests a high probability of further dilutive financing or insolvency.
- Investors should monitor the firm's ability to secure non-dilutive funding, as the current equity deficit of $11.6 million and lack of consistent revenue streams severely limit operational flexibility.
Verdict Logic
the company's current cash balance of $204,000 is insufficient to cover the $6.4 million quarterly free cash flow burn rate, signaling an imminent risk of severe shareholder dilution or insolvency.
WINT Growth Metrics
Windtree Therapeutics, Inc. (WINT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-312.06%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM99.09%
Return on Capital
10 Years-85.91%
5 Years-69.53%
3 Years-77.43%
Last Year-98.95%
Peers Comparison
Key metrics vs top competitors for Windtree Therapeutics, Inc. (WINT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.01 | $387 | -0.00 | — | — | -81.98% | 100% | |
| $15.63 | $1.31B | -29.49 | — | — | -38.92% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $44.01 | $2.62B | -6.18 | 48.03% | -639.84% | -34.11% | — | |
| $9.68 | $506.78M | -2.14 | -92.84% | -260.92% | -49.88% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — |
Compare WINT vs Peers
Windtree Therapeutics, Inc. (WINT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
WINT SEC Filings & Documents
Windtree Therapeutics, Inc. (WINT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when WINT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
WINT Frequently Asked Questions
Windtree Therapeutics, Inc. (WINT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Windtree Therapeutics, Inc.'s revenue?
Windtree Therapeutics, Inc. (WINT) reported $0.1M in revenue for fiscal year 2024. This represents a 10% decrease from $0.1M in 1995.
Is WINT profitable?
Windtree Therapeutics, Inc. (WINT) reported a net loss of $40.0M for fiscal year 2024.
Dividend & Returns
Does WINT pay dividends?
Yes, Windtree Therapeutics, Inc. (WINT) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.
What is WINT's return on equity?
Windtree Therapeutics, Inc. (WINT) has a return on equity (ROE) of -82.0%. Negative ROE indicates the company is unprofitable.
What is Windtree Therapeutics, Inc.'s free cash flow?
Windtree Therapeutics, Inc. (WINT) had negative free cash flow of $15.1M in fiscal year 2024, likely due to heavy capital investments.